Molecular Templates Inc logoValuEngine reduced shares of Molecular Templates (NASDAQ: MTEM) from a hold score to a promote score in a file issued on Thursday, August 1st, ValuEngine reports.

Several different equities analysts additionally currently commented on the stock. BidaskClub downgraded stocks of Molecular Templates from a preserve score to a promote rating in studies observe on Friday, July 26th. UBS Group assumed coverage on shares of Molecular Templates in a study document on Monday, April twenty-ninth. They set a purchase score and a $12.00 charge goal at the inventory. Finally, Zacks Investment Research reduces stocks of Molecular Templates from a purchase rating to a preserve rating in a research report on Wednesday, June 5th. Three funding analysts have rated the stock with a sell rating, and seven have given a buy score to the enterprise’s inventory. Molecular Templates presently has a consensus score of Hold and an average rate goal of $13.58.

NASDAQ: MTEM traded up $0.22 for the duration of midday buying and selling on Thursday, hitting $five.00. The business enterprise had a buying and selling quantity of 113,981 shares compared to its average quantity of 100,702. The enterprise has a short ratio of 3.Eleven, a modern-day ratio of 3.11, and a debt-to-equity ratio of zero.15. The corporation has a marketplace capitalization of $193.55 million, a PE ratio of -four.90, and a beta of 2.77. The inventory’s fifty-day transferring average rate is $6.41 and its 2 hundred-day moving common rate is $6.48. Molecular Templates has a 52-week low of $3.19 and a 52-week high of $8.Seventy-seven.

Molecular Templates (NASDAQ: MTEM) closing posted its quarterly income effects on Monday, August 12th. The biotechnology corporation mentioned ($zero.25) income consistent with the share for the area, missing the consensus estimate of ($zero.23) through ($0.02). The enterprise had sales of $5—forty-five million in the sector, compared to the consensus estimate of $6.00 million. Molecular Templates had a terrible return on equity of 27. Seventy-two % and a poor internet margin of 113.Eighty-five %. As a set, research analysts forecast that Molecular Templates will submit -0.Ninety-two earnings in line with a share for the current yr.

Several hedge price range has recently made changes to their positions in MTEM. BlackRock Inc. Grew its role in stocks of Molecular Templates through 26.Four% in the course of the fourth region. BlackRock Inc. Now owns 743,893 stocks of the biotechnology company’s stock really worth $three,0.5,000 after acquiring a further 155,240 shares over the last region. Bank of New York Mellon Corp grew its role in Molecular Templates by 37.6% inside the 4th sector. Bank of New York Mellon Corp now owns 36,854 stocks of the biotechnology corporation’s inventory worth $149,000 after shopping for an additional 10,076 shares over the last sector. Northern Trust Corp grew its position in Molecular Templates by 59.2% within the 4th sector. Northern Trust Corp now owns 165,677 stocks of the biotechnology employer’s stock worth $669,000 after shopping for an extra sixty-one 616 stocks over the last region. Geode Capital Management LLC grew its function in Molecular Templates with the aid of 78.1% within the 4th area. Geode Capital Management LLC now owns 134,069 stocks of the biotechnology company’s inventory worth $541,000 after shopping for a further 58,780 stocks over the past zone. Finally, Fosun International Ltd grew its function in Molecular Templates by 39.Three% inside the 1st region. Fosun International Ltd now owns 162,991 stocks of the biotechnology agency’s inventory worth $940,000 after shopping for an additional 45,968 stocks over the last region. Hedge price range and other institutional investors personal 38.29% of the company’s stock.

Molecular Templates, Inc, a clinical-stage oncology business enterprise, focuses on discovering and developing biological therapeutics for the treatment of most cancers and different diseases. The business enterprise typically develops a pipeline of engineered toxins in our bodies. Its lead drug candidate is MT-3724; this is in Phase II clinical trial to remedy relapsed/refractory diffuse big B-cellular lymphoma, and Phase II scientific trial for treating non-Hodgkin’s lymphoma.